Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012

被引:150
作者
Flys, T
Nissley, DV
Claasen, CW
Jones, D
Shi, CJ
Guay, LA
Musoke, P
Mmiro, F
Strathern, JN
Jackson, JB
Eshleman, JR
Eshleman, SH
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Sci Applicat Int Corp, Gene Regulat & Chromosome Biol Lab, Reverse Transcript & Mol Biol Sect, Basic Res Program, Frederick, MD USA
[3] NCI, Frederick, MD 21701 USA
[4] Makerere Univ, Dept Paediat, Kampala, Uganda
[5] Makerere Univ, Dept Obstet & Gynaecol, Kampala, Uganda
关键词
D O I
10.1086/430742
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The HIV Network for Prevention Trials (HIVNET) 012 trial showed that NVP resistance (NVPR) emerged in some women and children after the administration of single-dose nevirapine (SD-NVP). We tested whether K103N-containing human immunodeficiency virus (HIV)-1 variants persisted in women and infants 1 year or more after the administration of SD-NVP. Methods. We analyzed samples from 9 women and 5 infants in HIVNET 012 who had NVPR 6-8 weeks after the administration of SD-NVP. Samples were analyzed with the ViroSeq system and with 2 sensitive resistance assays, LigAmp and TyHRT. Results. ViroSeq detected the K103N mutation in 8 of 9 women and in 2 of 5 infants. LigAmp detected the K103N mutation at low levels in 8 of 9 women and in 4 of 5 infants. K103N was not detected by ViroSeq 12 24 months after the administration of SD-NVP but was detected by LigAmp in 3 of 9 women and in 1 of 5 infants. K103N was also detected in those samples by use of the TyHRT assay. Conclusions. K103N-containing variants persist in some women and infants for 1 year or more after the administration of SD-NVP. Sensitive resistance assays may provide new insight into the impact of antiretroviral drug exposure on HIV-1 evolution.
引用
收藏
页码:24 / 29
页数:6
相关论文
共 16 条
[1]  
CHALERMCHOKCHAR.A, 2004, 11 C RETR OPP INF SA, P111
[2]   Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants [J].
Collins, JA ;
Thompson, MG ;
Paintsil, E ;
Ricketts, M ;
Gedzior, J ;
Alexander, L .
JOURNAL OF VIROLOGY, 2004, 78 (02) :603-611
[3]   Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group protocol 316 [J].
Cunningham, CK ;
Chaix, ML ;
Rekacewicz, C ;
Britto, P ;
Rouzioux, C ;
Gelber, RD ;
Dorenbaum, A ;
Delfraissy, JF ;
Bazin, B ;
Mofenson, L ;
Sullivan, JL .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (02) :181-188
[4]   Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012 [J].
Eshleman, SH ;
Guay, LA ;
Mwatha, A ;
Cunningham, SP ;
Brown, ER ;
Musoke, P ;
Mmiro, F ;
Jackson, JB .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (06) :595-599
[5]   Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012) [J].
Eshleman, SH ;
Guay, LA ;
Mwatha, A ;
Brown, ER ;
Cunningham, SP ;
Musoke, P ;
Mmiro, F ;
Jackson, JB .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (02) :126-130
[6]   Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) [J].
Eshleman, SH ;
Mracna, M ;
Guay, LA ;
Deseyve, M ;
Cunningham, S ;
Mirochnick, M ;
Musoke, P ;
Fleming, T ;
Fowler, MG ;
Mofenson, LM ;
Mmiro, F ;
Jackson, JB .
AIDS, 2001, 15 (15) :1951-1957
[7]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802
[8]   Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy [J].
Jourdain, G ;
Ngo-Giang-Huong, N ;
Le Coeur, S ;
Bowonwatanuwong, C ;
Kantipong, P ;
Leechanachai, P ;
Ariyadej, S ;
Leenasirimakul, P ;
Hammer, S ;
Lallemant, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (03) :229-240
[9]  
KANTOR R, 2003, ANTIVIR THER, V8, pS85
[10]  
Little SJ, 2003, ANTIVIR THER, V8, pU113